BioRay's BR111 Receives Clinical Trial Approval for ROR1 Targeting Cancer Treatment BioRay's innovative ADC, BR111, targeting dual ROR1 epitopes, has received clinical trial approval from NMPA, marking a significant advancement in oncology.

BioRay's BR111 Receives Clinical Trial Approval for ROR1 Targeting Cancer Treatment #China #Shanghai #BioRay #BR111 #ROR1

BioRay's BR111 Drug Achieves NMPA Approval for Clinical Trials Targeting ROR1 in Cancer Treatment On December 19, 2024, BioRay Pharmaceutical announced that its innovative drug BR111 has received formal clinical trial approval from China’s NMPA.

BioRay's BR111 Drug Achieves NMPA Approval for Clinical Trials Targeting ROR1 in Cancer Treatment #China #Shanghai #BioRay #BR111 #ROR1

BioRay's Groundbreaking BR111 Cancer Drug Gains NMPA Approval for Clinical Trials BioRay Pharmaceutical has received NMPA approval for clinical trials of its innovative cancer drug BR111, a dual-epitope ADC aimed at ROR1.

BioRay's Groundbreaking BR111 Cancer Drug Gains NMPA Approval for Clinical Trials #China #Shanghai #cancer_therapy #BioRay #BR111

BioRay's BR111: A Breakthrough Dual-Epitope ADC Drug Approved for Trials BioRay's innovative ADC drug BR111 targeting ROR1 has gained NMPA trial approval, showcasing advanced cancer treatment potential across various malignancies.

BioRay's BR111: A Breakthrough Dual-Epitope ADC Drug Approved for Trials #China #Shanghai #BioRay #BR111 #ROR1

BioRay's Innovative BR111 ADC Drug Gains Approval for Clinical Trials in Cancer Treatment BioRay Pharmaceutical's BR111, a novel ROR1-targeting ADC drug, has received formal approval for clinical trials by NMPA, advancing cancer treatment.

BioRay's Innovative BR111 ADC Drug Gains Approval for Clinical Trials in Cancer Treatment #China #Shanghai #ADC #BioRay #BR111